I am a scientific manager with a robust background in scientific research, notably cancer biology and drug target discovery. I have a proven track record in industry and academia, having successfully delivered both research and operations projects to stakeholders in pharmaceutical and biotechnology companies as well as in academic institutions. I have published scientific articles in a range of high-impact journals and am a Lean Six Sigma Green Belt-certified process improvement champion. I am passionate about leveraging my skills to improve human health.
Currently, I serve as a Senior Scientific Manager at the Wellcome Sanger Institute (Cambridge, UK), overseeing laboratory management for the Human Genetics & Generative and Synthetic Genomics programmes. In this role, I ensure the smooth operation of the laboratories, manage diverse projects, help to maintain a safe working environment, and represent the research programmes at senior leadership meetings and committees.
At my previous company, Revvity, I was a Senior Scientist in the scientific services department, delivering CRISPR-based Functional Genomics and High Throughput Screening projects. I planned and executed custom CRISPR screening projects, contributed to internal and external R&D projects, conducted cell panel screening assays for drug discovery, and played a key role in process improvement initiatives and the writing of standard operating procedures (SOPs).
My extensive research background includes two postdoctoral fellowships. At the University of Edinburgh, I investigated dysregulated RNA splicing in colorectal cancer, utilizing advanced technologies such as mouse models, 3D organoid cell-systems, and CRISPR gene editing. Prior to that, at the Medical Research Council, I focused on the DNA damage response in animal cells, employing techniques like FACS, microscopy, qPCR, next-generation sequencing, Western blotting, and gene cloning.
The focus of my BBSRC-funded PhD was on small RNAs, specifically Y RNAs, and their behaviour during cellular stress. I also worked on microRNA-mediated gene silencing, and contributed to a project which developed a novel way of reducing sequencing bias of microRNAs, and this work led to a UK patent filing.
Publications:
RNA splicing is a key mediator of tumour cell plasticity and a therapeutic vulnerability in colorectal cancer. Nature Communications (2022), 13 (2791). Adam E. Hall, Sebastian Öther-Gee Pohl, Patrizia Cammareri, Stuart Aitken, Nicholas T. Younger, Michela Raponi, Caroline V. Billard, Alfonso Bolado Carrancio, Aslihan Bastem, Paz Freile, Fiona Haward, Ian R. Adams, Javier F. Caceres, Paula Preyzner, Alex von Kriegsheim, Malcolm G. Dunlop, Farhat V. Din and Kevin B. Myant.
Mechanistic insights into non-coding Y RNA processing. RNA Biology (2022), 19(1): 468-480. Martina Billmeier, Darrell Green, Adam E. Hall, Carly Turnbull, Archana Singh, Ping Xu, Simon Moxon and Tamas Dalmay.
RAC1B modulates intestinal tumourigenesis via modulation of WNT and EGFR signalling pathways. Nature Communications (2021), 12 (2335). Victoria Gudiño, Sebastian Öther-Gee Pohl, Caroline V. Billard, Patrizia Cammareri, Alfonso Bolado, Stuart Aitken, David Stevenson, Adam E. Hall, Mark Agostino, John Cassidy, Colin Nixon, Alex von Kriegsheim, Paz Friele, Linda Popplewell, George Dickson, Laura Murphy, Ann Wheeler, Malcolm Dunlop, Farhat Din, Douglas Strathdee, Owen J. Sansom and Kevin B. Myant.
The cytoskeleton adaptor protein ankyrin-1 is upregulated by p53 following DNA damage and alters cell migration. Cell Death & Disease (2016), 7 (4): e2184. Adam E. Hall, Wei-Ting Lu, Jack D. Godfrey, Alexey V. Antonov, Claudia Paicu, Simon Moxon, Tamas Dalmay, Ania Wilczynska, Patricia A.J. Muller and Martin Bushell.
Discovery of novel small RNAs in the quest to unravel genome complexity. Biochemical Society Transactions (2013), 41: 866–870. Adam E. Hall and Tamas Dalmay.
Y RNAs: recent developments. Biomolecular Concepts (2013), 4: 103-110. Adam E. Hall, Carly Turnbull, Tamas Dalmay.
Reducing ligation bias of small RNAs in libraries for next generation sequencing. Silence (2012), 3:4. Karim Sorefan, Helio Pais, Adam E. Hall, Ana Kozomara, Sam Griffiths-Jones, Vincent Moulton, Tamas Dalmay.
Biogenesis of Y RNA-derived small RNAs is independent of the microRNA pathway. FEBS Letters (2012), 586: 1226-1230. Francisco E Nicolas*, Adam E. Hall*, Tibor Csorba, Carly Turnbull, Tamas Dalmay. (* = joint first author).